Corvus Pharmaceuticals Q4 2021 Earnings Report
Key Takeaways
Corvus Pharmaceuticals reported a net loss of $9.2 million for the fourth quarter of 2021, with research and development expenses totaling $4.8 million. As of December 31, 2021, the company's cash, cash equivalents, and marketable securities amounted to $69.5 million.
Advanced three clinical programs for product candidates targeting CD73, the adenosine 2A receptor, and ITK.
Initiated mid-stage clinical trials in front-line treatment of lung cancer and renal cell cancer.
Partnership with Angel Pharmaceuticals has expanded clinical development of CPI-818 for T cell lymphomas into China.
Company had cash, cash equivalents and marketable securities totaling $69.5 million as of December 31, 2021.
Corvus Pharmaceuticals
Corvus Pharmaceuticals
Forward Guidance
Corvus expects full year 2022 net cash used in operating activities to be between $34 million and $36 million.